Lahore: Highnoon Laboratories Limited has scheduled an Extraordinary General Meeting (EGM) for its shareholders on September 02, 2024, at the company's registered office in Lahore. The primary agenda includes the confirmation of the previous Annual General Meeting minutes and the election of seven directors for a three-year term starting September 03, 2024.

The meeting will address significant business, including the retirement and re-election of directors. The directors due for retirement are Mr. Tausif Ahmad Khan, Dr. Adeel Abbas Haideri, Mr. Taufiq Ahmed Khan, Mr. Ghulam Hussain Khan, Mr. Tariq Wajid, Mr. Ramesh Alexander Iddamalgoda Elapata, and Mrs. Zainub Abbas. This election follows the guidelines set forth by the Companies Act 2017, ensuring governance compliance.

Shareholders are advised that the share transfer books will remain closed from August 27 to September 02, 2024. Only transfers received at the office of the company's Share Registrar, M/s Corplink (Private) Limited, by August 26, 2024, will be eligible for voting rights at the meeting. Proxy forms must be submitted at least 48 hours before the meeting to be considered effective.

In line with Securities and Exchange Commission of Pakistan regulations, shareholders can also attend the meeting via a video link facility. This requires prior registration, and interested parties should submit their credentials 48 hours before the meeting to the designated email address.

According to information available from the Pakistan Stock Exchange (PSX), the upcoming EGM is crucial for maintaining the strategic direction of Highnoon Laboratories as it reconstitutes its board. The election process is designed to ensure a diverse and competent board, reflective of shareholder interests and regulatory requirements.

The categories for the upcoming director elections are specifically outlined, including positions for one female director, two independent directors, and four other directors. Candidates wishing to contest the election must submit their intent and supporting documents by August 19, 2024, ensuring compliance with the regulatory framework and governance standards.

This meeting underscores Highnoon Laboratories' commitment to transparency and proper governance, essential for sustaining confidence among investors and stakeholders in the pharmaceutical sector.